| scholarly article | Q13442814 |
| P50 | author | Gerald I. Shulman | Q52509909 |
| Pascale Perret | Q59698812 | ||
| Stephen F Previs | Q106171714 | ||
| P2093 | author name string | G W Cline | |
| R Bergeron | |||
| L H Young | |||
| R R Russell | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | glucose | Q37525 |
| obesity | Q12174 | ||
| glycobiology | Q899224 | ||
| P304 | page(s) | 1076-1082 | |
| P577 | publication date | 2001-05-01 | |
| P1433 | published in | Diabetes | Q895262 |
| P1476 | title | Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats | |
| P478 | volume | 50 |
| Q35668005 | 5' adenosine monophosphate-activated protein kinase, metabolism and exercise |
| Q46620833 | 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside renders glucose output by the liver of the dog insensitive to a pharmacological increment in insulin |
| Q37608516 | 5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) effect on glucose production, but not energy metabolism, is independent of hepatic AMPK in vivo |
| Q34355140 | A Soluble Guanylate Cyclase–Dependent Mechanism Is Involved in the Regulation of Net Hepatic Glucose Uptake by Nitric Oxide in Vivo |
| Q37724203 | AICA-riboside (acadesine), an activator of AMP-activated protein kinase with potential for application in hematologic malignancies |
| Q39088631 | AICAR stimulation metabolome widely mimics electrical contraction in isolated rat epitrochlearis muscle |
| Q37030884 | AMP activated protein kinase: a next generation target for total metabolic control. |
| Q44176909 | AMP kinase activation ameliorates insulin resistance induced by free fatty acids in rat skeletal muscle |
| Q24541475 | AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation |
| Q22241925 | AMP-Activated Protein Kinase in Metabolic Control and Insulin Signaling |
| Q33688657 | AMP-activated Protein Kinase (AMPK): Does This Master Regulator of Cellular Energy State Distinguish Insulin Sensitive from Insulin Resistant Obesity? |
| Q33822976 | AMP-activated protein kinase (AMPK)α2 plays a role in determining the cellular fate of glucose in insulin-resistant mouse skeletal muscle |
| Q38214392 | AMP-activated protein kinase activators in diabetic ulcers: from animal studies to Phase II drugs under investigation |
| Q37864217 | AMP-activated protein kinase and metabolic control |
| Q36528251 | AMP-activated protein kinase and the regulation of glucose transport |
| Q37401935 | AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. |
| Q37872742 | AMP-activated protein kinase modulators: a patent review (2006 - 2010). |
| Q37411713 | AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease |
| Q36528537 | AMP-activated protein kinase signaling in metabolic regulation |
| Q42021544 | AMP-activated protein kinase-independent inhibition of hepatic mitochondrial oxidative phosphorylation by AICA riboside |
| Q38211516 | AMP-activated protein kinase: a key regulator of energy balance with many roles in human disease |
| Q35711953 | AMP-activated protein kinase: a master switch in glucose and lipid metabolism. |
| Q38026549 | AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases |
| Q92342120 | AMP-activated protein kinase: the current landscape for drug development |
| Q33183179 | AMP-activated protein kinase: the energy charge hypothesis revisited |
| Q49990861 | AMPK Re-Activation Suppresses Hepatic Steatosis but its Downregulation Does Not Promote Fatty Liver Development. |
| Q46118954 | AMPK activation with AICAR provokes an acute fall in plasma [K+]. |
| Q33824564 | AMPK activation: a therapeutic target for type 2 diabetes? |
| Q34268235 | AMPK activity and isoform protein expression are similar in muscle of obese subjects with and without type 2 diabetes |
| Q47781006 | AMPK in skeletal muscle function and metabolism. |
| Q35758306 | AMPK potentiates hypertonicity-induced apoptosis by suppressing NFκB/COX-2 in medullary interstitial cells |
| Q42534791 | AMPK-associated signaling to bridge the gap between fuel metabolism and hepatocyte viability |
| Q37153612 | AMPK: Lessons from transgenic and knockout animals |
| Q40420953 | ANGPTL4 mediates shuttling of lipid fuel to brown adipose tissue during sustained cold exposure |
| Q36943709 | Ablation of AMP-activated protein kinase alpha2 activity exacerbates insulin resistance induced by high-fat feeding of mice |
| Q36462591 | Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders |
| Q38288212 | Acute and chronic treatment of ob/ob and db/db mice with AICAR decreases blood glucose concentrations. |
| Q41062496 | Adenovirus-mediated chronic "hyper-resistinemia" leads to in vivo insulin resistance in normal rats |
| Q38089174 | Advances in the development of AMPK-activating compounds |
| Q34548928 | Apelin decreases lipolysis via G(q), G(i), and AMPK-Dependent Mechanisms |
| Q37271886 | Beyond AICA riboside: in search of new specific AMP-activated protein kinase activators |
| Q24614590 | CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations |
| Q28537870 | COH-SR4 reduces body weight, improves glycemic control and prevents hepatic steatosis in high fat diet-induced obese mice |
| Q34033452 | Caffeamide 36-13 Regulates the Antidiabetic and Hypolipidemic Signs of High-Fat-Fed Mice on Glucose Transporter 4, AMPK Phosphorylation, and Regulated Hepatic Glucose Production |
| Q37313758 | Can patients with type 2 diabetes be treated with 5'-AMP-activated protein kinase activators? |
| Q57545114 | Carbohydrate ingestion does not alter skeletal muscle AMPK signaling during exercise in humans |
| Q42429546 | Chronic AICAR-induced AMP-kinase activation regulates adipocyte lipolysis in a time-dependent and fat depot-specific manner in rats |
| Q39999797 | Chronic palmitate exposure inhibits AMPKalpha and decreases glucose-stimulated insulin secretion from beta-cells: modulation by fenofibrate. |
| Q77361711 | Current literature in diabetes |
| Q33361448 | Cytoplasmic signaling in the control of mitochondrial uproar? |
| Q55311614 | Dietary Flavonoids in the Prevention of T2D: An Overview. |
| Q64935591 | Dietary Supplementation of Vine Tea Ameliorates Glucose and Lipid Metabolic Disorder via Akt Signaling Pathway in Diabetic Rats. |
| Q28385788 | Dietary antiaging phytochemicals and mechanisms associated with prolonged survival |
| Q36867631 | Disruption of the cereblon gene enhances hepatic AMPK activity and prevents high-fat diet-induced obesity and insulin resistance in mice. |
| Q48306461 | Disturbed energy metabolism and muscular dystrophy caused by pure creatine deficiency are reversible by creatine intake |
| Q33747784 | Effect of acute exercise on AMPK signaling in skeletal muscle of subjects with type 2 diabetes: a time-course and dose-response study |
| Q42574960 | Effects of a leucine and pyridoxine-containing nutraceutical on body weight and composition in obese subjects. |
| Q46137914 | Effects of resistin expression on glucose metabolism and hepatic insulin resistance |
| Q47621460 | Electroacupuncture attenuates hepatic lipid accumulation via AMP-activated protein kinase (AMPK) activation in obese rats |
| Q35627476 | Electroacupuncture inhibits weight gain in diet-induced obese rats by activating hypothalamic LKB1-AMPK signaling |
| Q27832088 | Enhanced Sarcolemmal FAT/CD36 Content and Triacylglycerol Storage in Cardiac Myocytes From Obese Zucker Rats |
| Q30406455 | Enhancement of insulin-mediated rat muscle glucose uptake and microvascular perfusion by 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside |
| Q28567454 | Epinephrine and AICAR-induced PGC-1α mRNA expression is intact in skeletal muscle from rats fed a high-fat diet |
| Q28235151 | Fatty acid-inducible ANGPTL4 governs lipid metabolic response to exercise |
| Q33299468 | Gain-of-function R225W mutation in human AMPKgamma(3) causing increased glycogen and decreased triglyceride in skeletal muscle |
| Q46663577 | Glucose and lipid metabolism in relation to novel polymorphisms in the 5'-AMP-activated protein kinase gamma2 gene in Chinese |
| Q24336253 | Glucose stimulates cholesterol 7alpha-hydroxylase gene transcription in human hepatocytes |
| Q38507568 | Glucose transporters: cellular links to hyperglycemia in insulin resistance and diabetes. |
| Q45032176 | Glycine intake decreases plasma free fatty acids, adipose cell size, and blood pressure in sucrose-fed rats |
| Q53246282 | HL156A, a novel AMP-activated protein kinase activator, is protective against peritoneal fibrosis in an in vivo and in vitro model of peritoneal fibrosis. |
| Q50134179 | High-glucose toxicity is mediated by AICAR-transformylase/IMP cyclohydrolase and mitigated by AMP-activated protein kinase in Caenorhabditis elegans |
| Q39133938 | Impact of in vivo fatty acid oxidation blockade on glucose turnover and muscle glucose metabolism during low-dose AICAR infusion |
| Q48726745 | In vivo PET imaging with [(18)F]FDG to explain improved glucose uptake in an apolipoprotein A-I treated mouse model of diabetes. |
| Q53925808 | Increased NAD(P)H fluorescence with decreased blood flow in the steatotic liver of the obese Zucker rat. |
| Q40934119 | Inhibition of MEK1 Signaling Pathway in the Liver Ameliorates Insulin Resistance |
| Q35839705 | Insulin sensitive and resistant obesity in humans: AMPK activity, oxidative stress, and depot-specific changes in gene expression in adipose tissue |
| Q46800417 | Insulin signalling downstream of protein kinase B is potentiated by 5'AMP-activated protein kinase in rat hearts in vivo. |
| Q35134227 | Insulin-mediated capillary recruitment in skeletal muscle: is this a mediator of insulin action on glucose metabolism? |
| Q46425089 | Intravenous AICAR administration reduces hepatic glucose output and inhibits whole body lipolysis in type 2 diabetic patients |
| Q33919567 | LKB1 and AMPK and the regulation of skeletal muscle metabolism |
| Q36418845 | Leptin activates hepatic 5'-AMP-activated protein kinase through sympathetic nervous system and α1-adrenergic receptor: a potential mechanism for improvement of fatty liver in lipodystrophy by leptin |
| Q38333574 | Leptinomimetic effects of the AMP kinase activator AICAR in leptin-resistant rats: prevention of diabetes and ectopic lipid deposition. |
| Q37970188 | Lipid metabolism in skeletal muscle: generation of adaptive and maladaptive intracellular signals for cellular function |
| Q41775145 | Liver-Specific Activation of AMPK Prevents Steatosis on a High-Fructose Diet |
| Q33833542 | MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes. |
| Q36301403 | Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. |
| Q52620904 | Mitochondrial oxidative stress causes insulin resistance without disrupting oxidative phosphorylation. |
| Q38712159 | Multiple AMPK activators inhibit l-carnitine uptake in C2C12 skeletal muscle myotubes |
| Q47784531 | Nanoformulated copper/zinc superoxide dismutase exerts differential effects on glucose vs lipid homeostasis depending on the diet composition possibly via altered AMPK signaling |
| Q42805162 | Natural vanadium-containing Jeju ground water stimulates glucose uptake through the activation of AMP-activated protein kinase in L6 myotubes |
| Q34412650 | Nonalcoholic Fatty liver disease: pathogenesis and therapeutics from a mitochondria-centric perspective |
| Q34657286 | Nonalcoholic fatty liver disease: molecular pathways and therapeutic strategies |
| Q34481800 | Novel agents for managing dyslipidaemia |
| Q37528136 | Novel pharmacological approaches to combat obesity and insulin resistance: targeting skeletal muscle with 'exercise mimetics'. |
| Q35114594 | Novel targets and therapeutic strategies for type 2 diabetes |
| Q33668140 | PKA phosphorylates and inactivates AMPKalpha to promote efficient lipolysis |
| Q33995907 | Parenteral and enteral metabolism of anaplerotic triheptanoin in normal rats |
| Q54503212 | Phosphorylation of adipose triglyceride lipase Ser(404) is not related to 5'-AMPK activation during moderate-intensity exercise in humans. |
| Q39716350 | Preconditioning mice with activators of AMPK ameliorates ischemic acute kidney injury in vivo |
| Q35154210 | Predicting the development of the metabolically healthy obese phenotype. |
| Q41780034 | Prolonged AICAR-induced AMP-kinase activation promotes energy dissipation in white adipocytes: novel mechanisms integrating HSL and ATGL |
| Q37097698 | Recent advances in understanding integrative control of potassium homeostasis |
| Q24601195 | Recent advances in understanding the anti-diabetic actions of dietary flavonoids |
| Q34560800 | Reconstituted high-density lipoprotein infusion modulates fatty acid metabolism in patients with type 2 diabetes mellitus |
| Q43290384 | Reduced AMP-activated protein kinase activity in mouse skeletal muscle does not exacerbate the development of insulin resistance with obesity. |
| Q42449329 | Regulation of visceral and subcutaneous adipocyte lipolysis by acute AICAR-induced AMPK activation |
| Q38288019 | Relationship between AMPK and the transcriptional balance of clock-related genes in skeletal muscle |
| Q37554802 | Risk of developing diabetes and cardiovascular disease in metabolically unhealthy normal-weight and metabolically healthy obese individuals |
| Q34318349 | Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats. |
| Q38331700 | Short-term inhibition of SREBP-1c expression reverses diet-induced non-alcoholic fatty liver disease in mice. |
| Q35630601 | Small Molecule Kaempferol Promotes Insulin Sensitivity and Preserved Pancreatic β -Cell Mass in Middle-Aged Obese Diabetic Mice |
| Q35224775 | Small molecule adenosine 5'-monophosphate activated protein kinase (AMPK) modulators and human diseases |
| Q28584878 | Suppression of 5'-nucleotidase enzymes promotes AMP-activated protein kinase (AMPK) phosphorylation and metabolism in human and mouse skeletal muscle |
| Q42825276 | Synergistic effects of metformin, resveratrol, and hydroxymethylbutyrate on insulin sensitivity |
| Q37180980 | Targeting the AMPK pathway for the treatment of Type 2 diabetes |
| Q24554361 | The AMP-activated protein kinase alpha2 catalytic subunit controls whole-body insulin sensitivity |
| Q28594811 | The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism |
| Q22241897 | The blooming of the French lilac |
| Q53090551 | The inhibition of oleic acid induced hepatic lipogenesis and the promotion of lipolysis by caffeic acid via up-regulation of AMP-activated kinase. |
| Q35574164 | The role of AMP-activated protein kinase in fuel selection by the stressed heart |
| Q35614956 | The role of metformin in the management of NAFLD |
| Q42805365 | Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues |
| Q38419222 | Vascular AMPK as an attractive target in the treatment of vascular complications of obesity. |
| Q58788013 | l-Alanine activates hepatic AMP-activated protein kinase and modulates systemic glucose metabolism |
Search more.